Fundraising FoxGoldenrod Therapeutics, Inc.
Houston, US · Founded 2023 · Texas corporation · 1 known investors
Find your way into Goldenrod Therapeutics, Inc.
Sign up to see every warm intro you have to Goldenrod Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Goldenrod Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
Founders & leadership
Goldenrod Therapeutics, Inc. was founded in 2023 by Corey Hopkins.
CH
Corey HopkinsChair of the Department of Pharmaceutical Sciences and Director of the Center for Drug Design and Innovation at UNMC
DC
Dev ChatterjeeExecutiveDev Chatterjee is an executive officer at Goldenrod Therapeutics, a company developing phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders. He has experience in biomedical commercialization and de-risking early-stage therapeutic innovations from academic sources.
LL
Leo Linbeck IVExecutive
MW
Board
AV
Atul VaradhacharyBoard director
LL
TB
Thomas BrenninkmeijerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.2M disclosed across 1 round · 2026
▶$3.2MraisedJun 2026 · 2 investors · BiotechnologyRule 506(b)
▶$3.2MraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
- Dev ChatterjeeExecutive Officer
- Leo Linbeck IVExecutive Officer
- Mark WorschehExecutive Officer, Director
- Atul VaradhacharyExecutive Officer, Director
- Leo Linbeck IIIDirector
- Thomas BrenninkmeijerDirector
- Offering amount
- $6.5M
- Amount sold
- $3.2M
- Minimum investment
- $100K
- First sale
- May 2026
- Incorporated
- Corporation, Texas, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
CloudinaryCloudinary provides visual asset management and optimization tools for e-commerce teams, using AI-driven automation to enhance product images and videos for faster loading and improved conversion rates across sales channels.
WazeWorld's largest community-based traffic and navigation app.
Companies working in the same space as Goldenrod Therapeutics, Inc..
In the news
Frequently asked questions
- What does Goldenrod Therapeutics, Inc. do?
- Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
- Who founded Goldenrod Therapeutics, Inc.?
- Goldenrod Therapeutics, Inc. was founded by Corey Hopkins in 2023.
- Who are Goldenrod Therapeutics, Inc.'s investors?
- Goldenrod Therapeutics, Inc.'s investors include Fannin Goldenrod Holdings.
- How much funding has Goldenrod Therapeutics, Inc. raised?
- Goldenrod Therapeutics, Inc. has disclosed $3.2M raised across 1 round.
- Where is Goldenrod Therapeutics, Inc. headquartered?
- Goldenrod Therapeutics, Inc. is headquartered in Houston, US.